Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flexible vs fixed progestin-primed ovarian stimulation in Poseidon group 1 and 2
TCTR20250316002Phase 3
Key facts
- Status
- Recruiting
- Start
- Feb 2025
- Countries
- 1
- Sponsor
- Faculty of Medicine Research Fund
- Modality
- Small Molecules
- Conditions
- female infertility
01
Overview
Phase 3, randomised trial of hydroxyprogesterone caproate in female infertility (2 arms), sponsored by Faculty of Medicine Research Fund. Primary endpoint: Premature luteinizing hormone surge incidence. Started Feb 2025; status: recruiting.
02
Design
2 arms- Study design
- Randomized
Flexible PPOS
Flexible progestin-primed ovarian stimulation protocol with individualized timing of progestin initiation.
Fixed PPOS
Fixed progestin-primed ovarian stimulation protocol with progestin initiation on a predetermined cycle day.
03
Who it enrols
Women in Poseidon group 1 or 2 with low prognosis undergoing assisted reproductive treatment and eligible for progestin-primed ovarian stimulation.
04
Endpoints
Primary
Premature luteinizing hormone surge incidence
Beyond the preview
Go deeper on TCTR20250316002.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20250316002.